Microbiome-based therapeutics & Acute myeloid leukemia (AML) (therapy-associated infections)

Microbiome-based therapeutics in Acute myeloid leukemia (AML) (associated infections) focus on supportive care, treatment-response modulation, and post-therapy microbiome restoration. These therapeutics are not currently used as standalone anti-leukemia drugs.

The most supported methods include:
* Fecal microbiota transplantation
* Microbiome-preserving stewardship around antibiotics
* Potential metabolite- or taxa-directed strategies

Clinical evidence in AML is still in early stages and mostly non-definitive.
Ji et al. 2025 Metabolites 15(9): 568

Projects are:

• Fecal Microbiota Transplantation (FMT) & Acute myeloid leukemia (AML) (therapy-associated infections)


• MaaT011 & Acute myeloid leukemia (AML) (associated infections)

see also:
Acute myeloid leukemia (AML) (therapy-associated infections) & Drugs/Treatments